Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

9.580 -0.490 (-4.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
From Glancy Prongay & Murray LLP
Via Business Wire
Tempest to Participate in Upcoming Investor Conferences
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
“Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX
Via AB Newswire
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Year End 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
From Glancy Prongay & Murray LLP
Via Business Wire
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024
Via AB Newswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK
Via AB Newswire
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
MarketBeat Week in Review – 10/16 - 10/20
All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control 
Via MarketBeat
Topics Bonds Economy
The Secrets Behind a 4000% Biotech Stock Surge
Last Wednesday, shares of Tempest Therapeutics (NASDAQ: TPST), a small-cap stock you have probably never heard of, surged over 4000%. 
Via MarketBeat
Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)
Tempest Therapeutics, Inc. (NASDAQ: TPST) recently captivated investors with an unprecedented surge of over 3,000% in less than a week. 
Via Spotlight Growth
Tempest Adopts Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
Navigating the Roller Coaster of Recent Penny Stock Surges
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks. 
Via MarketBeat
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback